3 studies found for:    anti-KIR mAb and myeloma | Phase 1, 2
Show Display Options
Rank Status Study
1 Completed
Has Results
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Anti-KIR (1-7F9)
2 Completed A Study Evaluating the Activity, Safety and Pharmacology of Two Doses of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy
Condition: Multiple Myeloma
Intervention: Drug: IPH2101 Fully human anti-KIR monoclonal antibody
3 Active, not recruiting A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Conditions: Myeloma;   Smoldering Multiple Myeloma
Intervention: Drug: IHP2101 (anti-KIR)

Indicates status has not been verified in more than two years